IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

NCT05972460 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: IMM2510

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Collaborators

[object Object]
[object Object]